Clinical Research Directory

Inclusion Criteria: * Surgically resected primary squamous cell carcinomas (HNSCC) of the hypopharynx, oropharynx, larynx and oral cavity with pathological stage pT1-2 pN+ (pathological stage 1 ou 2 with node) or pT3-4 any pN (pathological stage 3 ou 4 with or without node) (UICC 7th edition, 2010), * Postoperative concomitant CRT based on radiotherapy and on cisplatinum, 3 cycles, 100mg/m² by cycle, * Patients who undergone macroscopically complete resection, * High-risk characteristics patients with one or more following criteria: such as invasion of two or more regional lymph nodes, extracapsular extension of nodal disease or microscopically-involved mucosal margins of resection, perineural involvement, vascular tumor embolism, * WHO (World Health Organization) performance status 0, 1 or 2, * Age: 18 years old up to 75 years old including, Exclusion Criteria: * Nasopharyngeal, paranasal sinuses, nasal cavity tumours or thyroid cancers * Sepsis at baseline * Distant metastasis * Other immunomodulating diets in the last month before inclusion * Parenteral nutrition at baseline * History of hypersensitivity and/or allergy to any component of Oral Impact ® * Patients with history of malignancies who are not disease-free for more than 5 years.